Stock of the Day

Cencora (COR)

$341.10

+$4.93 (+1.5%)

Market Cap: $64.15B

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Cencora Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

• The stock is currently trading at $341.10, which is below the average analyst price target of $370.85, suggesting potential upside of approximately 8.7% as Wall Street maintains a "Moderate Buy" consensus rating.
• Cencora, Inc. recently reported strong third-quarter results with earnings per share of $4.48, beating the consensus estimate of $4.35, while revenue of $84.75 billion also exceeded expectations, demonstrating robust operational performance.
• Institutional investors are showing renewed confidence, with Fort Washington Investment Advisors Inc. increasing its position by 81.5% in the third quarter and Forvis Mazars Wealth Advisors LLC boosting its stake by over 2,600%, indicating significant accumulation by professional funds.
• The company is actively integrating AI-driven demand sensing and logistics solutions, a strategic move that analysts believe could enhance efficiency and provide a competitive advantage over peers in the pharmaceutical distribution sector.
• Short interest has declined significantly over the past few months, dropping from 5.87 million shares in July to 3.92 million shares in September, which suggests that bearish sentiment is fading and short sellers are covering their positions.

Cencora Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

• The company carries a high debt-to-equity ratio of 3.53, which indicates a significant level of leverage that could pressure financial flexibility or increase interest costs if interest rates remain elevated.
• The dividend yield is relatively low at 0.73%, offering limited income generation for investors who prioritize cash flow, especially when compared to higher-yielding alternatives in the healthcare sector.
• Recent insider activity has been predominantly negative, with EVP Elizabeth Campbell selling 11,300 shares in August and CEO Robert P. Mauch selling 5,096 shares in January, which may signal a lack of confidence from company leadership at current price levels.
• The stock price of $341.10 is still well below the 52-week high of $377.54, and the company recently experienced a gap down of $14.28 in August, indicating volatility and potential downside risk if market sentiment shifts negatively.
• The price-to-earnings ratio of 25.34 is relatively high for a healthcare distributor, suggesting that the stock may be overvalued relative to its earnings growth, particularly if future earnings growth slows or faces headwinds from regulatory or market pressures.

Recent News

• Pennsylvania’s largest company is betting on AI from Conshohocken (msn.com)
• AI Disruption May Benefit Cencora More Than Hims & Hers (seekingalpha.com)
• Health System Pharmacy Outlook: Fall 2026 Report | Cencora (marketscreener.com)
• How Cencora Turns AI Velocity Into Patient Value (finance.yahoo.com)
• Insider Moves in PIMCO, Strive, Cencora, Grace, Banco Bradesco (tipranks.com)
• Leerink Partners Sticks to Its Buy Rating for Cencora (COR) (theglobeandmail.com)
• Cencora (COR) Receives a Hold from RBC Capital (theglobeandmail.com)